Commentary by Dan Roberts, Editor Living Well With Low Vision The low vision community has been shaken this past week by news of three patients whose vision was damaged by stem cell treatment at a Florida clinic in 2015. There is good reason for concern, but not about the future of stem cell therapy for [Read More]
Category: Research and Developments
OpRegen® for Dry-AMD in Trials
BioTime, Inc. is expanding its ongoing Phase I/IIa clinical trial for OpRegen® for treatment of dry AMD. by naming the first two sites that will treat patients in the U.S. Adi Mohanty, Co-Chief Executive Officer of BioTime, said, “We are honored to be working with two of the leading U.S. clinicians in ophthalmology, Dr. David [Read More]
Further Evidence of the Value of In-Home Occupational Therapy
A new study, published in the March 8 edition of Investigative Ophthalmology & Visual Science, has concluded that low-vision patients who improve in their daily living activities through at-home training with an occupational therapist (OT) have less severe symptoms of depression than similar patients who did not receive such training. Using outcomes from a recently [Read More]
Trials beginning for Emixustat Treatment of Stargardt Disease
Acucela has announced that the first patient has enrolled in a study to evaluate emixustat hydrochloride (“emixustat”) in subjects with Stargardt disease. Approximately 30 subjects will be enrolled at 4 to 6 clinical sites in the United States, with subjects taking oral doses of the drug once daily in the evening for one month. Emixustat [Read More]
“How soon will my good eye go bad?”
This is commonly-asked by people affected with unilateral age-related macular degeneration (AMD). AMD is a chronic and progressive disease, and the chances are good that it will eventually affect both eyes. The question about when that will happen has been addressed by a three-continent study published in January 2017 by the British Journal of Ophthalmology. Researchers [Read More]